Peptide hormone
Insulin
Insulin lispro has a subcutaneous half-life of 1 hour on the Humalog label, against 1.5 hours for regular human insulin; the app lists 1.5 hours for rapid-acting analog insulin.1
Insulin after one dose: 50% at ~1.5 h, 25% at 3 h, 12.5% at 4.5 h.
Drawn from the half-life in the app's model, ~1.5 h. The model's figures
- Compound
- Insulin
- Symbol
- INS
- Family
- Metabolic and mitochondrial peptides
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Insulin is a peptide hormone, and the app files it as an anabolic peptide hormone in its metabolic category. The US labels cited here describe four different products: a rapid acting human insulin analog (Humalog, insulin lispro), another rapid acting analog (NovoLog, insulin aspart), a short-acting human insulin (Humulin R) and an intermediate acting human insulin (Humulin N).1,2,3,4 The labels give initial US approval years of 1982 (Humulin R), 1996 (Humalog) and 2000 (NovoLog), and each states the same indication: improving glycemic control in people with diabetes mellitus.3,1,2 The app lists only the subcutaneous route, while the Humalog label lists subcutaneous injection, continuous subcutaneous infusion with an insulin pump, and intravenous infusion.1
The app's entry states that insulin is also used off-label in bodybuilding, and it grades the evidence as strong; that grade is the app's own and is not a conclusion of the sources here. Ip and colleagues (Touro University College of Pharmacy, Current Sports Medicine Reports, 2012) described a case series of 41 non-diabetic insulin users recruited through an internet survey, and Heidet and colleagues (Henri Mondor hospital group, Journal of Emergency Medicine, 2019) reported a bodybuilder who presented in coma from severe hypoglycemia.5,6
How it works
Sources in this part
The Humalog label states that "Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro".1 It adds that insulins "lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production".1 The same paragraph states that insulins "inhibit lipolysis and proteolysis, and enhance protein synthesis", and the NovoLog and Humulin R labels use matching wording for insulin aspart and human insulin.1,2,3 The Humalog label attributes weight gain with insulins to "the anabolic effects of insulin and the decrease in glucosuria".1 The Humalog label states that insulin lispro "has been shown to be equipotent to human insulin on a molar basis", with a more rapid onset and shorter duration than regular human insulin when given subcutaneously.1 The Humulin R label says that uptake and degradation of insulin "occurs predominantly in liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in the clearance of insulin."3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.5 h
- Bioavailability
- 100%
- Typical dose
- 2–10 IU/day
- Route
- SubQ
- Time to peak
- ~2 h
The app's figures are for rapid-acting analog insulin and are modeled with one compartment; the app's note states that short-acting, intermediate and long-acting basal insulins have very different kinetics. The table sets the app's figures beside the figures the sources report, and where a source differs the source's figure is printed next to the app's figure.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1.5 h | Insulin lispro, subcutaneous: 1 hour, against 1.5 hours for regular human insulin (Humalog label); insulin lispro intravenous: 0.85 hours (51 minutes) at 0.1 unit/kg and 0.92 hours (55 minutes) at 0.2 unit/kg; insulin aspart, subcutaneous: average apparent half-life of 81 minutes in 24 normal male volunteers (NovoLog label); regular human insulin, subcutaneous at 0.05 to 0.4 unit/kg: median apparent half-life of approximately 1.5 hours, range 40 minutes to 7 hours, and mean apparent half-life of approximately 3.6 hours, range 1.6 to 8.6 hours, after 50 and 100 units in healthy obese subjects (Humulin R label); NPH insulin, 0.4 unit/kg in healthy subjects: mean apparent half-life of approximately 4.4 hours, range 1 to 84 hours, with the label stating a true half-life cannot be accurately estimated (Humulin N label)1,2,3,4 |
| Bioavailability | 100% | Insulin lispro: absolute bioavailability after subcutaneous injection of 55% to 77% at 0.1 to 0.2 unit/kg (Humalog label); regular human insulin: 48% to 89% at 0.1 to 0.3 unit/kg (Humulin R label); insulin aspart: relative bioavailability at 0.15 units/kg compared with regular human insulin indicates the two are absorbed to a similar extent (NovoLog label)1,3,2 |
| Time to peak | ~2 h | Peak serum insulin: 30 to 90 minutes after insulin lispro at 0.1 to 0.4 unit/kg (Humalog label); median time to maximum concentration of 40 to 50 minutes for insulin aspart (NovoLog label); a mean of 33.3 minutes for lispro and 33.0 minutes for aspart in 20 healthy men (von Mach and colleagues); 36 to 150 minutes for regular human insulin at 0.05 to 0.4 unit/kg in healthy subjects, and a median of approximately 3 hours, range 1 to 8 hours, after 50 and 100 units in healthy obese subjects (Humulin R label); about 4 hours, range 1 to 12 hours, for NPH insulin at 0.4 unit/kg in healthy subjects (Humulin N label)1,2,7,3,4 |
| Time of maximum glucose-lowering effect | App lists no figure | Insulin lispro U-100: median 2.4 hours, range 0.5 to 4.7 hours (Humalog label); insulin aspart: between 1 and 3 hours (NovoLog label); regular human insulin: approximately 3 hours, range 20 minutes to 7 hours (Humulin R label); NPH insulin: median 6.5 hours, range 2.8 to 13 hours (Humulin N label)1,2,3,4 |
| Duration of action | 6 h (the app's figure) | Insulin aspart: 3 to 5 hours, from 22 patients with type 1 diabetes given 0.15 units/kg (NovoLog label); regular human insulin: terminates after approximately 8 hours, range 3 to 14 hours, at 0.05 to 0.4 units/kg, and approximately 18 hours, range approximately 12 to 24 hours, after 50 and 100 units in obese subjects (Humulin R label)2,3 |
The app's 100% bioavailability is higher than the figures printed on the labels cited (55% to 77% for insulin lispro, 48% to 89% for regular human insulin), its 6 hour duration is longer than the 3 to 5 hours on the NovoLog label and shorter than the approximately 8 hours on the Humulin R label, and its half-life of 1.5 hours matches the regular human insulin figure on the Humalog and Humulin R labels rather than the lispro figure of 1 hour.1,3,2 The app's time to peak of about 2 hours is closer to the labels' time of maximum glucose-lowering effect than to their time of maximum serum insulin concentration.1,2
Variability is stated by the labels themselves: the Humalog label says the time course of action "may vary considerably in different individuals or within the same individual".1 The Humalog label calls its onset, peak and duration parameters "general guidelines" and says absorption is affected by "the site of injection, exercise, and other variables".1 The Humalog label states that "The effects of age, gender, race, obesity, pregnancy, or smoking on the pharmacokinetics of HUMALOG have not been studied."1
Lispro against aspart, and ultra rapid lispro
von Mach and colleagues (II Medical Department, University of Mainz, Experimental and Clinical Endocrinology and Diabetes, 2002) compared the two rapid-acting analogs in a randomized, double-blind crossover study of 20 fasting healthy men given a single subcutaneous injection of 0.05 U/kg.7 Maximal insulin concentration was 20.8 +/- 1.1 mU/l for lispro and 24.6 +/- 1.3 mU/l for aspart (p = 0.032), and time to maximal insulin concentration did not differ (33.3 +/- 2.6 against 33.0 +/- 2.6 minutes, not significant).7 The lowest glucose was 3.2 +/- 0.1 mmol/l after 50 minutes with aspart and 3.4 +/- 0.1 mmol/l after 60 minutes with lispro, and the authors conclude that the results "indicate a more rapid absorption of insulin aspart in comparison to insulin lispro".7 At 50 minutes glucose was 3.2 +/- 0.1 mmol/l with aspart against 3.5 +/- 0.1 mmol/l with lispro (p = 0.026), the time to lowest glucose was 59.3 +/- 3.4 minutes with aspart against 63.5 +/- 5.3 minutes with lispro (not significant), and minimal C-peptide was reached in both groups after 105 minutes.7 The PubMed record for this trial does not state a funder, the authors' limitations or adverse events.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| DCCT Research Group, New England Journal of Medicine, 19939 | Randomized, parallel, masking none; sponsor NIDDK9,10 | 1441 people with insulin-dependent diabetes, 726 without retinopathy and 715 with mild retinopathy, aged 13 to 39 years9,10 | Intensive therapy (pump or three or more daily injections) against conventional therapy (one or two daily injections); mean 6.5 years9 | Retinopathy risk reduced by 76 percent (95 percent CI 62 to 85) in the primary-prevention cohort; chief adverse event a two-to-threefold increase in severe hypoglycemia9 |
| Humalog label, 12-month type 1 diabetes trial1 | Randomized, parallel, open-label, active-controlled; reported on the Eli Lilly label1 | Patients with type 1 diabetes: insulin lispro n=81, regular human insulin n=86; mean age 31 years, range 12 to 701 | Lispro immediately before meals against Humulin R 30 to 45 minutes before meals, with Humulin U basal insulin; 12 months1 | HbA1c change -0.1 ± 0.9 against 0.1 ± 1.1, treatment difference 0.4 (0.0, 0.8); severe hypoglycemia in 14 (17%) against 18 (21%); no episodes of diabetic ketoacidosis in either group1 |
| von Mach and colleagues, Experimental and Clinical Endocrinology and Diabetes, 20027 | Randomized, double-blind crossover7 | 20 fasting healthy men7 | Single subcutaneous injection of lispro or aspart, 0.05 U/kg; 5-hour profiles7 | Maximal insulin concentration detected after 40 minutes in both groups, 20.8 +/- 1.1 mU/l (lispro) against 24.6 +/- 1.3 mU/l (aspart), p = 0.032; insulin t max 33.3 +/- 2.6 against 33.0 +/- 2.6 minutes and time to lowest glucose 63.5 +/- 5.3 against 59.3 +/- 3.4 minutes, both not significant7 |
| Leohr and colleagues, Clinical Therapeutics, 20208 | Randomized, 6-period, subject- and investigator-blind crossover; sponsor Eli Lilly8,11 | 42 healthy subjects8 | Single subcutaneous 7, 15 or 30 U of ultra rapid lispro or Humalog, with a 10-hour euglycemic clamp8 | Exposure beyond 3 hours 45%-52% lower and duration of exposure 67-86 minutes shorter with ultra rapid lispro; overall exposure and total glucose infused similar8 |
| Ip and colleagues, Current Sports Medicine Reports, 20125 | Internet-based survey, case series, posted February to June 20095 | 41 non-diabetic insulin users, 97.6% male, mean age 30.7 ± 9.2 years5 | Not stated in the PubMed record5 | Hypoglycemia reported by 56.8%; one person reported unconsciousness; 95.1% also used anabolic steroids5 |
| Heidet and colleagues, Journal of Emergency Medicine, 20196 | Case report6 | One 30-year-old male bodybuilder6 | Not stated in the PubMed record6 | Coma from severe hypoglycemia needing iterative glucose infusions, later linked to cryptic insulin injections6 |
Deeper analysis: the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group reported the trial in the New England Journal of Medicine in 1993; it randomly assigned 1441 people with insulin-dependent diabetes to intensive or conventional insulin therapy and followed them for a mean of 6.5 years.9 The comparison is between two insulin regimens, one guided by frequent blood glucose monitoring, and not between insulin and no insulin.9 The registry entry gives the eligibility as insulin dependence shown by deficient C-peptide secretion, an age of 13 to 39 years, and the absence of hypertension, hypercholesterolemia and severe diabetic complications or medical conditions.10 In the primary-prevention cohort, intensive therapy reduced the adjusted mean risk of developing retinopathy by 76 percent (95 percent confidence interval 62 to 85).9 In the secondary-intervention cohort, it slowed progression of retinopathy by 54 percent (39 to 66) and reduced development of proliferative or severe nonproliferative retinopathy by 47 percent (14 to 67).9 In the two cohorts combined, microalbuminuria fell by 39 percent (21 to 52), albuminuria by 54 percent (19 to 74) and clinical neuropathy by 60 percent (38 to 74).9 The authors report that "The chief adverse event associated with intensive therapy was a two-to-threefold increase in severe hypoglycemia".9 Their conclusion reads "Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM".9 The registry entry names the National Institute of Diabetes and Digestive and Kidney Diseases as lead sponsor, lists the masking as none, the status as completed, and the start and completion as August 1983 and April 1993; the PubMed record lists research support from the US government (P.H.S.).10,9 The PubMed record does not list the authors' stated limitations or individual author ties, and the group is credited as the first author.9
Deeper analysis: ultra rapid lispro against lispro
Leohr and colleagues reported the study in Clinical Therapeutics in 2020; five of the eight listed authors give Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, as their affiliation, and the registry names Eli Lilly and Company as lead sponsor.8,11 The registry lists the study as phase 1 and completed.11 Across all three doses, insulin lispro appeared in the serum 2-5 minutes faster and exposure in the first 15 minutes was 6- to 8-fold greater with the ultra rapid formulation than with Humalog.8 Onset of insulin action was 7-9 minutes faster, and insulin action beyond 4 hours was reduced by 32%-45%.8 The registry's adverse event module lists 0 deaths and 0 serious adverse events in each of six dose groups of 40 or 41 participants, and lists other adverse events (nausea, injection site reaction, headache) in 7, 5 and 14 participants in the 7, 15 and 30 U ultra rapid lispro groups and 8, 6 and 5 participants in the 7, 15 and 30 U Humalog groups; the PubMed record does not state the authors' limitations.11,8 The participants were healthy, and no outcome in this study describes people with diabetes.8
Deeper analysis: reports of insulin misuse in bodybuilding
Ip and colleagues (Touro University College of Pharmacy, 2012) posted a 99-item internet survey on fitness, bodybuilding, weightlifting and anabolic steroid discussion boards between February and June 2009 and describe 41 non-diabetic insulin users.5 The typical user was 30.7 ± 9.2 years old, male (97.6%) and white (86.8%), 95.1% also used anabolic steroids, and users reported 16.2 ± 5.6 performance-enhancing drugs in a yearly routine.5 Hypoglycemia "was reported by most of the subjects (56.8%), and one individual reported unconsciousness".5 The survey was posted on discussion boards of fitness, bodybuilding, weightlifting and anabolic steroid web sites, and the PubMed record does not state the funder, the authors' limitations or any dose.5 Heidet and colleagues (Henri Mondor hospital group, Créteil, France, 2019) describe one 30-year-old male bodybuilder in coma from severe hypoglycemia of unknown cause, needing iterative glucose infusions, later traced to cryptic insulin injections.6 The authors write that "In strength athletes, especially amateurs, the recourse to performance-enhancement drugs (e.g., insulin) is frequent".6 The PubMed record for the case report does not state a funder or limitations, and a single case cannot give a rate.6
Doses reported in studies and on labels
The app's typical dose is 2 to 10 IU/day. The Humalog label states that "The dosage of HUMALOG must be individualized based on the route of administration and the individual's metabolic needs, blood glucose monitoring results and glycemic control goal".1
| Source | Dose, route and duration | People |
|---|---|---|
| Humalog label, pharmacokinetics1 | Subcutaneous 0.1 to 0.4 unit/kg of insulin lispro; intravenous 0.1 and 0.2 unit/kg boluses | Healthy volunteers1 |
| Humalog label, type 1 diabetes trial1 | Insulin lispro immediately before meals against Humulin R 30 to 45 minutes before meals; 12 months; baseline short-acting dose 0.3 ± 0.1 units/kg/day | 81 on lispro and 86 on Humulin R, type 1 diabetes1 |
| NovoLog label, pharmacodynamics2 | Single subcutaneous 0.15 units/kg pre-meal dose of insulin aspart | 22 patients with type 1 diabetes2 |
| Humulin R label, pharmacokinetics3 | Subcutaneous 0.05 to 0.4 unit/kg; 50 units and 100 units in a separate study | Healthy subjects; healthy obese subjects for 50 and 100 units3 |
| Humulin N label, pharmacodynamics4 | Subcutaneous 0.4 unit/kg of NPH insulin on 4 occasions | 16 healthy subjects4 |
| von Mach and colleagues, 20027 | Single subcutaneous 0.05 U/kg of lispro or aspart, crossover; 5-hour profiles | 20 fasting healthy men7 |
| Leohr and colleagues, 20208 | Single subcutaneous 7, 15 or 30 U of ultra rapid lispro or Humalog, crossover; 10-hour clamp | 42 healthy subjects8 |
| DCCT Research Group, 19939 | Intensive: external insulin pump or three or more daily injections; conventional: one or two daily injections; mean 6.5 years | 1441 people with insulin-dependent diabetes9 |
Side effects reported
The Humalog label states that "Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG".1 It adds that "Severe hypoglycemia can cause seizures, may be life-threatening, or cause death" and that it "can happen suddenly".1 It states that the risk "is highest when the glucose lowering effect of the insulin is maximal".1 The labels state that excess insulin "may cause hypoglycemia and hypokalemia".2,3 The Humalog label states that all insulins "cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia" and that "Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death".1 The Humalog label lists these adverse reactions: "hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash".1 In controlled trials, pruritus with or without rash was seen in 17 patients on regular human insulin (n=2969) and 30 on Humalog (n=2944).1 The label also states that severe, life-threatening generalized allergy including anaphylaxis can occur.1 The Humalog label lists two contraindications: "during episodes of hypoglycemia" and "in patients who are hypersensitive to insulin lispro or to any of the excipients in HUMALOG".1 Pens and cartridges "must never be shared between patients, even if the needle is changed".1 In the 12-month label trial in type 1 diabetes, severe hypoglycemia was reported in 14 (17%) on Humalog and 18 (21%) on Humulin R.1 In the DCCT, severe hypoglycemia rose two-to-threefold with intensive therapy, and in the survey of 41 non-diabetic users 56.8% reported hypoglycemia.9,5
Bloodwork and markers
The app lists fasting glucose and HbA1c as the markers to monitor. HbA1c was the glycemic outcome in the Humalog label's 12-month trial, while the DCCT record reports complication outcomes (retinopathy, albuminuria, neuropathy).1,9 In the study by von Mach and colleagues, plasma glucose, serum C-peptide and insulin were followed for 5 hours, and C-peptide at 40 minutes was lower with aspart (225 +/- 21 pmol/l) than with lispro (309 +/- 33 pmol/l; p = 0.031).7 The Humalog label flags potassium because insulins shift potassium into cells, and notes that people with renal or hepatic impairment "may be at higher risk of hypoglycemia".1
Regulatory and anti-doping status
The US labels give diabetes mellitus as the indication for Humalog, NovoLog and Humulin R, with initial US approval in 1996, 2000 and 1982.1,2,3 The WADA 2026 Prohibited List places "Insulins and insulin-mimetics, e.g. S519, S597" at S4.4.2 within S4, hormone and metabolic modulators.12 Section S4 is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".12 The list states that "Those in classes S4.3 and S4.4 are non-Specified Substances".12
Storage and handling
Sources in this part
The Humalog label states "Protect from direct heat and light" and "Do not freeze and do not use if it has been frozen".1 For Humalog U-100 and U-200 it adds that "When stored at room temperature, HUMALOG U-100 and U-200 can only be used for a total of 28 days".1 The NovoLog label states "Store unused NOVOLOG in a refrigerator between 2°C to 8°C (36°F to 46°F)" and "Do not freeze NOVOLOG and do not use NOVOLOG if it has been frozen".2 The Humulin R patient information states "Store all unopened vials in the refrigerator at 36° to 46°F (2° to 8°C)."3
What is not known
The app's 100% bioavailability, 6 hour duration and 2 to 10 IU/day range do not match a figure on the Humalog, NovoLog or Humulin labels cited here, which describe diabetes use.1,2,3 A PubMed query for exogenous insulin, muscle mass and resistance training in healthy non-diabetic people (randomized) returned no records on 16 November 2026, and a ClinicalTrials.gov query for insulin with bodybuilding or muscle hypertrophy in healthy people returned 162 studies, none of whose 20 displayed titles named insulin. These queries do not rule out trials they missed. A PubMed query on insulin abuse and bodybuilding returned two records, a 2019 English case report and a 1998 German-language case report, and one on insulin misuse by athletes returned 17 records. The Humalog label states that "Human metabolism studies have not been conducted" for insulin lispro, with animal studies indicating its metabolism is identical to regular human insulin.1 Kinetics of long-acting basal insulins (glargine, detemir, degludec) are not described by the sources cited here; a DailyMed query for insulin glargine returned 0 labels on 16 November 2026. The Humulin N label states that for NPH insulin "a true half-life cannot be accurately estimated" from the terminal slope.4
Frequently asked questions
What is the half-life of insulin?
What is the bioavailability of insulin?
How long does insulin take to reach its peak?
How long does rapid-acting insulin last?
Do all types of insulin have the same half-life?
Is insulin banned by WADA?
Yes, the WADA 2026 Prohibited List includes "Insulins and insulin-mimetics" at S4.4.2, under a section prohibited at all times, in and out of competition.12
What is the most common side effect of insulin?
Is insulin approved in the United States?
Has insulin been tested for building muscle in healthy people?
A PubMed query for exogenous insulin, muscle mass and resistance training in healthy non-diabetic people (randomized) returned no records on 16 November 2026. The reports that were identified are an internet survey of 41 non-diabetic users and a case report of one bodybuilder with severe hypoglycemia.5,6
Guides, tools and comparisons
References
- Eli Lilly and Company. Humalog (insulin lispro) injection. US prescribing information, DailyMed record version 87, 2026. DailyMed label
- Novo Nordisk. NovoLog (insulin aspart) injection. US prescribing information, DailyMed record version 34, 2023. DailyMed label
- Eli Lilly and Company. Humulin R (insulin human) injection. US prescribing information, DailyMed record version 35, 2026. DailyMed label
- Eli Lilly and Company. Humulin N (insulin isophane human) injectable suspension. US prescribing information, DailyMed record version 50, 2025. DailyMed label
- Ip EJ, et al. Weightlifting's risky new trend: a case series of 41 insulin users. Curr Sports Med Rep 2012. PMID 22777326
- Heidet M, et al. Severe Hypoglycemia Due to Cryptic Insulin Use in a Bodybuilder. J Emerg Med 2019. PMID 30527564
- von Mach MA, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002. PMID 12518253
- Leohr J, et al. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clin Ther 2020. PMID 32900535
- Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. PMID 8366922
- National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Control and Complications Trial (DCCT). ClinicalTrials.gov NCT00360815. NCT00360815
- Eli Lilly and Company. A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants. ClinicalTrials.gov NCT03286751. NCT03286751
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list